Browse our 650+ Publications​

Latest Publications

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.

Frigault MJ, et al.
Blood Advances
April 2023
Authors and Affiliates
Matthew J. Frigault,1,2 Michael R. Bishop,3 Jacalyn Rosenblatt,4 Elizabeth K. O’Donnell,1,2 Noopur Raje,1,2 Daniella Cook,1,2 Andrew J. Yee,1,2 Emma Logan,4 David E. Avigan,4 Andrzej Jakubowiak,3 Kit Shaw,5 Heather Daley,5 Sarah Nikiforow,5 Faith Griffin,6 Christine Cornwell,6 Angela Shen,6 Christopher Heery,6 and Marcela V. Maus1,2 1Massachusetts General Hospital Cancer Center, Boston, MA; 2Harvard Medical School, Boston, MA; 3David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL; 4Beth Israel Deaconess Medical Center, Boston, MA; 5Dana Farber Cancer Institute, Cell Manipulation Core Facility, Brookline, MA; and 6Arcellx, Inc., Gaithersburg, MD

Impact of BCG vaccination on the repertoire of human γδ T cell receptors

Xia M, et al.
April 2023
Authors and Affiliates
Mei Xia 1, Azra Blazevic 1, Andrew Fiore-Gartland 2, Daniel F Hoft 1,3; 1 Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, United States. 2 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 3 Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States.

Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

Pai JA, et al.
April 2023
Authors and Affiliates
Joy A Pai 1, Matthew D Hellmann 2, Jennifer L Sauter 3, Marissa Mattar 4, Hira Rizvi 5, Hyung Jun Woo 6, Nisargbhai Shah 7, Evelyn M Nguyen 8, Fathema Z Uddin 7, Alvaro Quintanal-Villalonga 7, Joseph M Chan 7, Parvathy Manoj 7, Viola Allaj 7, Marina K Baine 3, Umesh K Bhanot 9, Mala Jain 9, Irina Linkov 9, Fanli Meng 6, David Brown 6, Jamie E Chaft 10, Andrew J Plodkowski 11, Mathieu Gigoux 12, Helen H Won 6, Triparna Sen 10, Daniel K Wells 13, Mark T A Donoghue 6, Elisa de Stanchina 4, Jedd D Wolchok 14, Brian Loomis 6, Taha Merghoub 14, Charles M Rudin 15, Andrew Chow 16, Ansuman T Satpathy 17; 1 Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Program, Stanford University, Stanford, CA, USA. 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4 Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5 Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6 Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Cancer Biology Program, Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 11 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 13 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Santa Ana Bio, Alameda, CA, USA. 14 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 16 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: chowa1@mskcc.org. 17 Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Program, Stanford University, Stanford, CA, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, Stanford University, Stanford, CA, USA. Electronic address: satpathy@stanford.edu.

Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders

John J, et al.
April 2023
Authors and Affiliates
Jessy John 1, Samantha M Y Chen 2, Rachel A Woolaver 2, Huaibin Ge 1, Monika Vashisht 1, Ziyu Huang 3, Zhangguo Chen 1, Jing H Wang 1,4; 1 UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States. 2 Department of Immunology and Microbiology, University of Colorado, School of Medicine, Aurora, CO, United States. 3 UPMC Hillman Cancer Center Biostatistics Facility, University of Pittsburgh, Pittsburgh, PA, United States. 4 Department of Immunology, University of Pittsburgh, Pittsburgh, PA, United States.

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

Shenderov E, et al.
April 2023
Authors and Affiliates
Eugene Shenderov 1,2, Angelo M De Marzo 3,4,5, Tamara L Lotan 3,4,5, Hao Wang 6, Sin Chan 3, Su Jin Lim 6, Hongkai Ji 7, Mohamad E Allaf 5, Carolyn Chapman 3, Paul A Moore 8, Francine Chen 8, Kristina Sorg 9, Andrew M White 9, Sarah E Church 9, Briana Hudson 9, Paul A Fields 10, Shaohui Hu 11, Samuel R Denmeade 3, Kenneth J Pienta 3, Christian P Pavlovich 5, Ashley E Ross 12, Charles G Drake 13, Drew M Pardoll 3,14, Emmanuel S Antonarakis 3,14,15; 1 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu. 2 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu. 3 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4 Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5 Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 6 Department of Oncology Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, MD, USA. 7 Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 8 MacroGenics, Inc., Rockville, MD, USA. 9 NanoString Technologies Inc., Seattle, WA, USA. 10 Adaptive Biotechnologies, Seattle, WA, USA. 11 CDI Labs, Baltimore, MD, USA. 12 Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 13 Immuno-Oncology, Janssen, Horsham, PA, USA. 14 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. 15 University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.

T cell immunity is key to the pandemic endgame: How to measure and monitor it

Schwarz M, et al,
April 2023
Authors and Affiliates
Megan Schwarz 1,2, Slim Mzoughi 1,2, Daniel Lozano-Ojalvo 3, Anthony T Tan 4, Antonio Bertoletti 4, Ernesto Guccione 1,2,5; 1 Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, USA. 2 Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA. 3 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, NY, USA. 4 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. 5 Bioinformatics for Next Generation Sequencing (BiNGS) Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.

Younes A, et al.
Blood Advances
April 2023
Authors and Affiliates
Anas Younes,1 John M. Burke,2 Bruce D. Cheson,3 Catherine S. Diefenbach,4 Silvia Ferrari,5 Uwe H. Hahn,6 Eliza A. Hawkes,7 Cyrus Khan,8 Izidore S. Lossos,9 Gerardo Musuraca,10 Monica Tani,11 Umberto Vitolo,12 Sam Yuen,13 Aparna Raval,14 Mahesh Shivhare,15 Tina G. Nielsen,16 Gila Sellam,16 Jeff P. Sharman,17 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; 2Rocky Mountain Cancer Centers & US Oncology, Aurora, CO, USA; 3Georgetown University Hospital, Washington, DC, USA*; 4 Clinical Lymphoma program, Perlmutter Cancer Center at NYU Langone Health, New York City, NY, USA; 5Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; 6Department of Haematology, Royal Adelaide and Queen Elizabeth Hospital, Adelaide, SA, Australia; 7Department of Haematology,Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia; 8Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA; 9Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA; 10Hematology unit, IRCCS, Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy; 11Division of Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy; 12Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy; 13Department of Haematology, Calvary Mater, Newcastle, NSW, Australia; 14Oncology Biomarker Development,Genentech, Inc, South San Francisco, CA, USA**; 15Data and statistical Science, Roche Products Ltd, Welwyn Garden City, United Kingdom; 16Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; 17US Oncology Research, Willamette Valley Cancer Institute / US Oncology Research, Eugene, OR, USA

Interpretable artificial intelligence model for accurate identification of medical conditions using immune repertoire

Zhao Y, et al.
April 2023
Authors and Affiliates
Yu Zhao 1, Bing He 1, Zhimeng Xu 1, Yidan Zhang 1,2, Xuan Zhao 1, Zhi-An Huang 1,3, Fan Yang 1, Liang Wang 1, Lei Duan 2, Jiangning Song 1,4, Jianhua Yao 1; 1 AI Lab, Tencent, Shenzhen, China. 2 School of Computer Science, Sichuan University, Chengdu, China. 3 Center for Computer Science and Information Technology, City University of Hong Kong Dongguan Research Institute, Dongguan, China. 4 Monash Biomedicine Discovery Institute and Monash Data Futures Institute, Monash University, Melbourne, VIC 3800, Australia.

Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer

Yoshida-Court K, et al.
April 2023
Authors and Affiliates
Kyoko Yoshida-Court 1, Tatiana V Karpinets 2, Aparna Mitra 1, Travis N Solley 1, Stephanie Dorta-Estremera 3, Travis T Sims 4, Andrea Y Delgado Medrano 1, Molly B El Alam 1, Mustapha Ahmed-Kaddar 1, Erica J Lynn 1, K Jagannadha Sastry 5, Jianhua Zhang 2, Andrew Futreal 2, Alpa Nick 6,7, Karen Lu 4, Lauren E Colbert 1, Ann H Klopp 1; 1 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. 2 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. 3 Comprehensive Cancer Center, Cancer Biology, Department of Microbiology and Zoology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico. 4 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. 5 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America. 6 Saint Thomas Health/Ascension, Nashville, TN, United States of America. 7 Tennessee Oncology, Nashville, Tennessee, United States of America.